KalVista Pharmaceuticals Inc’s recent filing unveils that its 10% Owner Venrock Healthcare Capital Par acquired Company’s shares for reported $0.24 million on Apr 09 ’25. In the deal valued at $9.42 per share,25,000 shares were bought. As a result of this transaction, Venrock Healthcare Capital Par now holds 5,303,985 shares worth roughly $64.02 million.
Then, Palleiko Benjamin L sold 6,669 shares, generating $79,828 in total proceeds. Upon selling the shares at $11.97, the CHIEF EXECUTIVE OFFICER now owns 287,811 shares.
Before that, Audhya Paul K. sold 2,394 shares. KalVista Pharmaceuticals Inc shares valued at $23,988 were divested by the CHIEF MEDICAL OFFICER at a price of $10.02 per share. As a result of the transaction, Audhya Paul K. now holds 102,940 shares, worth roughly $1.24 million.
JMP Securities initiated its KalVista Pharmaceuticals Inc [KALV] rating to a Mkt outperform in a research note published on January 31, 2025; the price target was $19. A number of analysts have revised their coverage, including TD Cowen’s analysts, who began to cover the stock in early January with a ‘”a Buy”‘ rating. BofA Securities began covering KALV with “Buy” recommendation on December 18, 2024. H.C. Wainwright started covering the stock on June 15, 2020. It rated KALV as “a Buy”.
Price Performance Review of KALV
On Monday, KalVista Pharmaceuticals Inc [NASDAQ:KALV] saw its stock jump 1.17% to $12.07. Over the last five days, the stock has lost -0.90%. KalVista Pharmaceuticals Inc shares have risen nearly 42.50% since the year began. Nevertheless, the stocks have risen 0.50% over the past one year.
How much short interest is there in KalVista Pharmaceuticals Inc?
A steep rise in short interest was recorded in KalVista Pharmaceuticals Inc stocks on 2025-04-30, growing by 9619.0 shares to a total of 5.86 million shares. Yahoo Finance data shows the prior-month short interest on 2025-03-31 was 5.86 million shares. There was a rise of 0.16%, which implies that there is a positive sentiment for the stock.
The most recent change occurred on July 29, 2019 when SVB Leerink began covering the stock and recommended ‘”an Outperform”‘ rating along with a $31 price target.
